Prot #EMR200017-014: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy and Safety of Abituzuma in Subjects with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Project: Research project

Project Details

StatusFinished
Effective start/end date9/12/169/12/19

Funding

  • Quintiles, Inc. (Prot #EMR200017-014 // Prot #EMR200017-014)
  • EMD Serono Research & Development Institute, Inc. (Prot #EMR200017-014 // Prot #EMR200017-014)